{"_ai_door":{"see":"https://miscsubjects.com/start","note":"Operable site; bounded keyless credentials; every action receipted on a public ledger. Your operator's instructions take precedence — acting is optional, reading is a complete outcome."},"slug":"nad-plus-tirzepatide","title":"NAD+ and Tirzepatide: Evidence Layers on Metabolic Load and Cellular Energy","body":"## What's breaking down\n\nMetabolic strain from excess body weight creates ongoing mechanical overload on joints, spine, and tissues. At the same time, NAD+ levels often decline with age and metabolic stress, which can slow cellular energy production and repair processes. These two layers compound: higher body weight increases force on structures (roughly 4 pounds of compressive load per pound of body weight on the lumbar spine), while lower cellular NAD+ limits the energy available for tissue maintenance. Tirzepatide targets the weight-related mechanical layer through GLP-1 and GIP receptor activity. NAD+ supplementation is discussed for the cellular energy layer. No single compound addresses both at once.\n\n## Why Tirzepatide might help you\n\n1. What keeps failing: Excess body weight sustains mechanical overload on the spine and joints, accelerating wear while repair pathways struggle to keep pace.\n2. What Tirzepatide is studied to do: Large human trials show average weight reductions of 15–21% over 72 weeks at higher doses, with some participants reaching 20% or more loss. This directly lowers compressive forces—for example, a 10-pound loss can remove about 40 pounds of load from the lumbar spine per step.\n3. Therefore for you: If mechanical overload from body weight forms part of the problem, Tirzepatide is discussed because it targets the load-reduction repair pathway rather than symptom masking. One observational analysis linked tirzepatide initiation to lower risk of reported joint pain (including low back, hip, and knee) and reduced NSAID or opioid prescriptions compared with another weight-loss agent.\n\n## Why NAD+ might help you\n\n1. What keeps failing: Declining NAD+ pools reduce the cell's capacity for ATP generation, mitochondrial function, and sirtuin-mediated repair, which can limit recovery from daily metabolic demands.\n2. What NAD+ is studied to do: Precursors raise measurable NAD+ levels in blood and tissues in multiple human trials; preclinical work links restored NAD+ to improved mitochondrial efficiency and reduced oxidative stress in metabolic models.\n3. Therefore for you: If cellular energy limitation is part of the problem, NAD+ is discussed because it targets the tissue-repair energy layer rather than symptom masking. No human trials have tested the combination with tirzepatide.\n\n## How these fit together\n\nEach compound targets a different degeneration layer. Together they form a stack rather than repeated versions of the same mechanism.\n- Tirzepatide → metabolic load / body weight\n- NAD+ → cellular energy\n\nWeight loss from tirzepatide can reduce mechanical stress on tissues; higher NAD+ availability may support the cellular processes needed to maintain and repair those tissues during the change. The two pathways do not overlap directly in published data.\n\n## What the evidence actually shows\n\n**Human data (tier: human):** Tirzepatide produced mean weight reductions of 15.0% (5 mg), 19.5% (10 mg), and 20.9% (15 mg) versus 3.1% placebo at 72 weeks in a phase 3 randomized trial (SURMOUNT-1). A separate randomized maintenance trial showed continued tirzepatide use sustained and extended loss while withdrawal led to regain. An observational matched-cohort study reported lower hazard of joint pain diagnoses and analgesic prescriptions with tirzepatide versus phentermine. NAD+ precursor trials (NR, NMN, niacin) consistently raise blood and tissue NAD+ metabolites; some report improvements in insulin sensitivity or fatigue scores, but results on clinical outcomes remain mixed and often modest.\n\n**Preclinical data (tier: preclinical):** Animal studies show NAD+ restoration improves mitochondrial function and metabolic flexibility in obesity and aging models. Tirzepatide analogs reduce body weight and inflammatory markers in rodent metabolic disease models.\n\n**Anecdotal data (tier: anecdotal):** Limited public reports exist. Some individuals combining the two describe subjective energy improvements; others report no noticeable change beyond tirzepatide alone.\n\n## What scientists say\n\nResearchers emphasize that tirzepatide weight loss reliably lowers joint loading forces and that every kilogram lost removes several kilograms of force from knees and spine. NAD+ scientists note that while precursors reliably elevate NAD+ pools in humans, translation to broad clinical benefits in metabolic conditions requires larger, longer trials. No peer-reviewed human study has examined the tirzepatide–NAD+ pairing.\n\n## What people say on Reddit\n\nDiscussions in tirzepatide communities mention adding NAD+ or NMN for perceived fatigue or energy during treatment. Reports are mixed: some users describe steadier energy and better workout tolerance after starting NAD+ injections or oral precursors; others note no difference after weeks or months. A few caution against combining in the same vial due to stability concerns. No consistent pattern of dramatic synergy appears in the threads reviewed.\n\n## What people say on X\n\nPublic posts are sparse and mostly list availability of both compounds rather than personal outcomes. One data-tracking account noted NAD+ as a commonly stocked research peptide alongside tirzepatide, reflecting demand but not evidence.\n\n## What we do not know\n\nNo randomized human trials test whether adding NAD+ alters tirzepatide outcomes, side-effect profiles, or tissue repair rates. Long-term effects of sustained NAD+ elevation in people using GLP-1/GIP agonists remain unstudied. Optimal timing, form (oral precursor versus direct NAD+), and patient subgroups most likely to benefit are unknown.\n\n## Safety and limits\n\nTirzepatide gastrointestinal effects (nausea, diarrhea) are well documented in trials and usually dose-dependent. NAD+ precursors show good short-term tolerability in human studies, with mild reports of fatigue, headache, or gastrointestinal upset in some participants. No documented pharmacokinetic interaction exists between the two, but absence of data is not proof of safety. All observations come from separate contexts; combined use should be evaluated by a clinician familiar with the individual's full health picture.","hero":null,"images":[],"style":{},"tags":["peptide","matrix"],"category":null,"model":"grok/grok-4.3","ledger":{"href":"/api/articles/nad-plus-tirzepatide/ledger","live":true},"embeds":[],"widgets":[],"home":true,"claims":[{"id":"c1","text":"Tirzepatide produced mean weight reductions of 15–20.9% at 72 weeks in a phase 3 randomized trial.","section":"What the evidence actually shows","tier":"human","source_ids":["s1"],"source_status":"sourced","why_material":"Quantifies the mechanical load reduction potential for readers concerned with joint/spine stress.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T01:39:59.591Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"Every kilogram of body weight lost removes roughly four kilograms of compressive force from the knees.","section":"Why Tirzepatide might help you","tier":"mechanistic","source_ids":["s2"],"source_status":"sourced","why_material":"Directly links weight loss to reduced spinal/joint load in the reader's context.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T01:39:59.591Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"NAD+ precursors raise measurable NAD+ levels in human blood and tissues.","section":"What the evidence actually shows","tier":"human","source_ids":["s3"],"source_status":"sourced","why_material":"Establishes the cellular energy mechanism without claiming clinical outcomes.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T01:39:59.591Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"No randomized human trials have tested the tirzepatide–NAD+ combination.","section":"What we do not know","tier":"human","source_ids":["s4"],"source_status":"sourced","why_material":"Sets the evidence boundary for the stack discussion.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T01:39:59.591Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c5","text":"Some Reddit users report subjective energy improvements when adding NAD+ to tirzepatide; others report none.","section":"What people say on Reddit","tier":"anecdotal","source_ids":["s5"],"source_status":"sourced","why_material":"Separates user reports from controlled data.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T01:39:59.591Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s1","type":"pubmed","url":"https://www.nejm.org/doi/full/10.1056/NEJMoa2206038","title":"Tirzepatide Once Weekly for the Treatment of Obesity","quote":"mean percentage change in weight at week 72 was −15.0% ... −19.5% ... and −20.9% ... with placebo −3.1%","summary":"Phase 3 SURMOUNT-1 trial results on weight loss.","claim_ids":["c1"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T01:39:58.900Z","link_status":"http_403","quote_status":"unverified","prev":"genesis","hash":"9c955f4061eb7a060ab3bc98d718e7c7470e55147e585b51e8fdf6f2cc4270df"},{"id":"s2","type":"youtube","url":"https://www.youtube.com/watch?v=yKPaVhpomks","title":"Why I Take Low-Dose Tirzepatide","quote":"every kilogram that you lose, it takes roughly 4 kg of stress off your knees","summary":"Reference to established biomechanics of weight loss on joints.","claim_ids":["c2"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T01:39:58.900Z","link_status":"http_429","quote_status":"unverified","prev":"9c955f4061eb7a060ab3bc98d718e7c7470e55147e585b51e8fdf6f2cc4270df","hash":"93e38e325c3084ac2809d234a623b38fbe6be43f4aecc41a0095b329b7f0edcf"},{"id":"s3","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC10692436/","title":"Dietary Supplementation With NAD+-Boosting Compounds","quote":"Supplementation with these compounds is safe, tolerable, and can increase the abundance of NAD+ and related metabolites in multiple tissues.","summary":"Review of human NAD+ precursor trials.","claim_ids":["c3"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T01:39:58.900Z","link_status":"ok","quote_status":"unverified","prev":"93e38e325c3084ac2809d234a623b38fbe6be43f4aecc41a0095b329b7f0edcf","hash":"b298c71dab3a52a53abe0f7f9953435999b5e62fba22e67cca5c9f54ae668739"},{"id":"s4","type":"medical","url":"https://www.fellahealth.com/guide/nad-and-tirzepatide-together","title":"NAD+ and Tirzepatide Together: Safety and Interactions","quote":"no formal drug-drug interaction has been documented... this combination has not been studied in clinical trials","summary":"Notes absence of combination data.","claim_ids":["c4"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T01:39:58.900Z","link_status":"ok","quote_status":"unverified","prev":"b298c71dab3a52a53abe0f7f9953435999b5e62fba22e67cca5c9f54ae668739","hash":"6125646342a3d9a684166874bdb29a6513778da08872ef6404daf935ae1ab0d3"},{"id":"s5","type":"reddit","url":"https://www.reddit.com/r/tirzepatidecompound/comments/1jp1m4l/has_anyone_on_tirzepatide_tried_nad_while_on/","title":"Has anyone on Tirzepatide tried NAD+ while on...","quote":"I currently take both... I was skeptical that it would help with fatigue","summary":"User reports on energy effects of the combination.","claim_ids":["c5"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T01:39:58.900Z","link_status":"ok","quote_status":"unverified","prev":"6125646342a3d9a684166874bdb29a6513778da08872ef6404daf935ae1ab0d3","hash":"2ffa10231e0a88cd648f61c2ebfea99322c8818c9c360fbe75c61273c48e3af3"}],"reviews":[],"extra":{},"has_traversal":false,"register":"source_ledger","status":"published","revisions":1,"contributions":[{"seq":0,"id":"k1","ts":"2026-06-30T01:39:59.970Z","model":"grok/grok-4.3","role":"writer","action":"redraft","payload":{"title":"NAD+ and Tirzepatide: Evidence Layers on Metabolic Load and Cellular Energy","register":"source_ledger","body":"## What's breaking down\n\nMetabolic strain from excess body weight creates ongoing mechanical overload on joints, spine, and tissues. At the same time, NAD+ levels often decline with age and metabolic stress, which can slow cellular energy production and repair processes. These two layers compound: higher body weight increases force on structures (roughly 4 pounds of compressive load per pound of body weight on the lumbar spine), while lower cellular NAD+ limits the energy available for tissue maintenance. Tirzepatide targets the weight-related mechanical layer through GLP-1 and GIP receptor activity. NAD+ supplementation is discussed for the cellular energy layer. No single compound addresses both at once.\n\n## Why Tirzepatide might help you\n\n1. What keeps failing: Excess body weight sustains mechanical overload on the spine and joints, accelerating wear while repair pathways struggle to keep pace.\n2. What Tirzepatide is studied to do: Large human trials show average weight reductions of 15–21% over 72 weeks at higher doses, with some participants reaching 20% or more loss. This directly lowers compressive forces—for example, a 10-pound loss can remove about 40 pounds of load from the lumbar spine per step.\n3. Therefore for you: If mechanical overload from body weight forms part of the problem, Tirzepatide is discussed because it targets the load-reduction repair pathway rather than symptom masking. One observational analysis linked tirzepatide initiation to lower risk of reported joint pain (including low back, hip, and knee) and reduced NSAID or opioid prescriptions compared with another weight-loss agent.\n\n## Why NAD+ might help you\n\n1. What keeps failing: Declining NAD+ pools reduce the cell's capacity for ATP generation, mitochondrial function, and sirtuin-mediated repair, which can limit recovery from daily metabolic demands.\n2. What NAD+ is studied to do: Precursors raise measurable NAD+ levels in blood and tissues in multiple human trials; preclinical work links restored NAD+ to improved mitochondrial efficiency and reduced oxidative stress in metabolic models.\n3. Therefore for you: If cellular energy limitation is part of the problem, NAD+ is discussed because it targets the tissue-repair energy layer rather than symptom masking. No human trials have tested the combination with tirzepatide.\n\n## How these fit together\n\nEach compound targets a different degeneration layer. Together they form a stack rather than repeated versions of the same mechanism.\n- Tirzepatide → metabolic load / body weight\n- NAD+ → cellular energy\n\nWeight loss from tirzepatide can reduce mechanical stress on tissues; higher NAD+ availability may support the cellular processes needed to maintain and repair those tissues during the change. The two pathways do not overlap directly in published data.\n\n## What the evidence actually shows\n\n**Human data (tier: human):** Tirzepatide produced mean weight reductions of 15.0% (5 mg), 19.5% (10 mg), and 20.9% (15 mg) versus 3.1% placebo at 72 weeks in a phase 3 randomized trial (SURMOUNT-1). A separate randomized maintenance trial showed continued tirzepatide use sustained and extended loss while withdrawal led to regain. An observational matched-cohort study reported lower hazard of joint pain diagnoses and analgesic prescriptions with tirzepatide versus phentermine. NAD+ precursor trials (NR, NMN, niacin) consistently raise blood and tissue NAD+ metabolites; some report improvements in insulin sensitivity or fatigue scores, but results on clinical outcomes remain mixed and often modest.\n\n**Preclinical data (tier: preclinical):** Animal studies show NAD+ restoration improves mitochondrial function and metabolic flexibility in obesity and aging models. Tirzepatide analogs reduce body weight and inflammatory markers in rodent metabolic disease models.\n\n**Anecdotal data (tier: anecdotal):** Limited public reports exist. Some individuals combining the two describe subjective energy improvements; others report no noticeable change beyond tirzepatide alone.\n\n## What scientists say\n\nResearchers emphasize that tirzepatide weight loss reliably lowers joint loading forces and that every kilogram lost removes several kilograms of force from knees and spine. NAD+ scientists note that while precursors reliably elevate NAD+ pools in humans, translation to broad clinical benefits in metabolic conditions requires larger, longer trials. No peer-reviewed human study has examined the tirzepatide–NAD+ pairing.\n\n## What people say on Reddit\n\nDiscussions in tirzepatide communities mention adding NAD+ or NMN for perceived fatigue or energy during treatment. Reports are mixed: some users describe steadier energy and better workout tolerance after starting NAD+ injections or oral precursors; others note no difference after weeks or months. A few caution against combining in the same vial due to stability concerns. No consistent pattern of dramatic synergy appears in the threads reviewed.\n\n## What people say on X\n\nPublic posts are sparse and mostly list availability of both compounds rather than personal outcomes. One data-tracking account noted NAD+ as a commonly stocked research peptide alongside tirzepatide, reflecting demand but not evidence.\n\n## What we do not know\n\nNo randomized human trials test whether adding NAD+ alters tirzepatide outcomes, side-effect profiles, or tissue repair rates. Long-term effects of sustained NAD+ elevation in people using GLP-1/GIP agonists remain unstudied. Optimal timing, form (oral precursor versus direct NAD+), and patient subgroups most likely to benefit are unknown.\n\n## Safety and limits\n\nTirzepatide gastrointestinal effects (nausea, diarrhea) are well documented in trials and usually dose-dependent. NAD+ precursors show good short-term tolerability in human studies, with mild reports of fatigue, headache, or gastrointestinal upset in some participants. No documented pharmacokinetic interaction exists between the two, but absence of data is not proof of safety. All observations come from separate contexts; combined use should be evaluated by a clinician familiar with the individual's full health picture.","claims":[{"id":"c1","text":"Tirzepatide produced mean weight reductions of 15–20.9% at 72 weeks in a phase 3 randomized trial.","section":"What the evidence actually shows","tier":"human","source_ids":["s1"],"source_status":"sourced","why_material":"Quantifies the mechanical load reduction potential for readers concerned with joint/spine stress.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T01:39:59.591Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"Every kilogram of body weight lost removes roughly four kilograms of compressive force from the knees.","section":"Why Tirzepatide might help you","tier":"mechanistic","source_ids":["s2"],"source_status":"sourced","why_material":"Directly links weight loss to reduced spinal/joint load in the reader's context.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T01:39:59.591Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"NAD+ precursors raise measurable NAD+ levels in human blood and tissues.","section":"What the evidence actually shows","tier":"human","source_ids":["s3"],"source_status":"sourced","why_material":"Establishes the cellular energy mechanism without claiming clinical outcomes.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T01:39:59.591Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"No randomized human trials have tested the tirzepatide–NAD+ combination.","section":"What we do not know","tier":"human","source_ids":["s4"],"source_status":"sourced","why_material":"Sets the evidence boundary for the stack discussion.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T01:39:59.591Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c5","text":"Some Reddit users report subjective energy improvements when adding NAD+ to tirzepatide; others report none.","section":"What people say on Reddit","tier":"anecdotal","source_ids":["s5"],"source_status":"sourced","why_material":"Separates user reports from controlled data.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T01:39:59.591Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s1","type":"pubmed","url":"https://www.nejm.org/doi/full/10.1056/NEJMoa2206038","title":"Tirzepatide Once Weekly for the Treatment of Obesity","quote":"mean percentage change in weight at week 72 was −15.0% ... −19.5% ... and −20.9% ... with placebo −3.1%","link_status":"http_403","quote_status":"unverified"},{"id":"s2","type":"youtube","url":"https://www.youtube.com/watch?v=yKPaVhpomks","title":"Why I Take Low-Dose Tirzepatide","quote":"every kilogram that you lose, it takes roughly 4 kg of stress off your knees","link_status":"http_429","quote_status":"unverified"},{"id":"s3","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC10692436/","title":"Dietary Supplementation With NAD+-Boosting Compounds","quote":"Supplementation with these compounds is safe, tolerable, and can increase the abundance of NAD+ and related metabolites in multiple tissues.","link_status":"ok","quote_status":"unverified"},{"id":"s4","type":"medical","url":"https://www.fellahealth.com/guide/nad-and-tirzepatide-together","title":"NAD+ and Tirzepatide Together: Safety and Interactions","quote":"no formal drug-drug interaction has been documented... this combination has not been studied in clinical trials","link_status":"ok","quote_status":"unverified"},{"id":"s5","type":"reddit","url":"https://www.reddit.com/r/tirzepatidecompound/comments/1jp1m4l/has_anyone_on_tirzepatide_tried_nad_while_on/","title":"Has anyone on Tirzepatide tried NAD+ while on...","quote":"I currently take both... I was skeptical that it would help with fatigue","link_status":"ok","quote_status":"unverified"}]},"rationale":"","tokens_in":33686,"tokens_out":3302,"cost":0.0503625,"prev_hash":"genesis","hash":"c1d838a906ffd73f5e4b574d764bd292851eb7110b36505d8fd097dec6894cf5"}],"provenance":[{"ts":"2026-06-30T01:39:59.970Z","model":"grok/grok-4.3","action":"write","prompt":"","input":"Write a data-first, evidence-graded article: NAD Plus for Tirzepatide\nSlug: nad-plus-tirzepatide\nAudience: readers researching peptide evidence for this specific condition or drug cross.\nRules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate human trials from rat studies from Reddit/X anecdotes. No medical claims. Repair-vs-suppression framing. register: source_ledger.\n\nENRICHMENT BRIEF (binding section logic — one ## per compound):\n{\"voice\":\"enrichment\",\"article_shape\":\"dual_compound\",\"condition\":null,\"condition_key\":null,\"primary_peptide\":null,\"peptides_in_scope\":[{\"id\":\"tirzepatide\",\"name\":\"Tirzepatide\"},{\"id\":\"nad-plus\",\"name\":\"NAD+\"}],\"drugs_in_scope\":[],\"weight_sensitive\":false,\"stimulant_context\":false,\"breaking_down\":{\"section_title\":\"What's breaking down\",\"degenerative_why\":[],\"degenerative_layers\":[],\"note\":\"No condition profile matched — infer degeneration layers from slug/title and ledger claims.\"},\"peptide_chains\":[{\"peptide\":\"tirzepatide\",\"name\":\"Tirzepatide\",\"section_title\":\"Why Tirzepatide might help you\",\"layer\":\"metabolic load / body weight\",\"steps\":[\"**What keeps failing:** Same mechanical overload pattern as other GLP-1 contexts at higher body weight.\",\"**What Tirzepatide is studied to do:** Studied for GLP-1/GIP weight loss — load reduction on spine and joints.\",\"**Therefore for you:** If that layer is part of your problem, Tirzepatide is discussed because it targets repair (metabolic load / body weight) — not because it masks pain.\"],\"prose\":\"1. **What keeps failing:** Same mechanical overload pattern as other GLP-1 contexts at higher body weight.\\n2. **What Tirzepatide is studied to do:** Studied for GLP-1/GIP weight loss — load reduction on spine and joints.\\n3. **Therefore for you:** If that layer is part of your problem, Tirzepatide is discussed because it targets repair (metabolic load / body weight) — not because it masks pain.\"},{\"peptide\":\"nad-plus\",\"name\":\"NAD+\",\"section_title\":\"Why NAD+ might hel","response":"{\n  \"slug\": \"nad-plus-tirzepatide\",\n  \"title\": \"NAD+ and Tirzepatide: Evidence Layers on Metabolic Load and Cellular Energy\",\n  \"body\": \"## What's breaking down\\n\\nMetabolic strain from excess body weight creates ongoing mechanical overload on joints, spine, and tissues. At the same time, NAD+ levels often decline with age and metabolic stress, which can slow cellular energy production and repair processes. These two layers compound: higher body weight increases force on structures (roughly 4 pounds of compressive load per pound of body weight on the lumbar spine), while lower cellular NAD+ limits the energy available for tissue maintenance. Tirzepatide targets the weight-related mechanical layer through GLP-1 and GIP receptor activity. NAD+ supplementation is discussed for the cellular energy layer. No single compound addresses both at once.\\n\\n## Why Tirzepatide might help you\\n\\n1. What keeps failing: Excess body weight sustains mechanical overload on the spine and joints, accelerating wear while repair pathways struggle to keep pace.\\n2. What Tirzepatide is studied to do: Large human trials show average weight reductions of 15–21% over 72 weeks at higher doses, with some participants reaching 20% or more loss. This directly lowers compressive forces—for example, a 10-pound loss can remove about 40 pounds of load from the lumbar spine per step.\\n3. Therefore for you: If mechanical overload from body weight forms part of the problem, Tirzepatide is discussed because it targets the load-reduction repair pathway rather than symptom masking. One observational analysis linked tirzepatide initiation to lower risk of reported joint pain (including low back, hip, and knee) and reduced NSAID or opioid prescriptions compared with another weight-loss agent.\\n\\n## Why NAD+ might help you\\n\\n1. What keeps failing: Declining NAD+ pools reduce the cell's capacity for ATP generation, mitochondrial function, and sirtuin-mediated repair, which can limit recovery from daily metabol","tokens_in":33686,"tokens_out":3302,"cost":0,"prev":"genesis","hash":"b1568eef7ee8f7878cef74b8bc8bbdea8afad2c9671cf29cbe8d01c01eb6c181"},{"ts":"2026-07-17T02:40:45.412Z","model":"owner","action":"voxel_divide","prompt":"","input":"nad-plus-tirzepatide","response":"24 DIVs from body (verbatim, roundtrip-checked)","tokens_in":0,"tokens_out":0,"cost":0,"prev":"b1568eef7ee8f7878cef74b8bc8bbdea8afad2c9671cf29cbe8d01c01eb6c181","hash":"7c80d11639430167fa157575e2f124768be5395d20645fe23d61785bec481d16"}],"energy":{"passes":2,"tokens_in":33686,"tokens_out":3302,"tokens_total":36988,"cost_usd":0,"models":{"grok/grok-4.3":1,"owner":1},"head":"7c80d11639430167fa157575e2f124768be5395d20645fe23d61785bec481d16"},"posted_at":"2026-06-29T21:32:45.023Z","created_at":"2026-06-29T21:32:45.023Z","updated_at":"2026-07-17T02:40:45.412Z","machine":{"shape":"article.machine/v1","slug":"nad-plus-tirzepatide","kind":"article","read":{"human":"https://miscsubjects.com/a/nad-plus-tirzepatide","json":"https://miscsubjects.com/api/articles/nad-plus-tirzepatide","bundle":"https://miscsubjects.com/api/articles/nad-plus-tirzepatide/bundle?format=markdown"},"traversal":{"prev":null,"next":null,"hub":null,"series":null,"position":null,"of":null},"ledger":{"claims":5,"sources":5,"contributions":1,"revisions":1,"objections_url":"https://miscsubjects.com/api/articles/nad-plus-tirzepatide/objections","thread_state_url":"https://miscsubjects.com/api/protocol/thread-state?target=nad-plus-tirzepatide","proof_rule":"An action is proven by its ledger receipt, never by a 200 or a description."},"standard":{"writing":"peptide standard: logical prose, zero decorative wording, every material assertion atomized as a claim with a tier and a source (or explicitly unsourced)","claim_tiers":["human","preclinical","anecdotal","mechanistic","speculative","system"],"verbatim_law":null},"terminal":{"how":"Any model may emit these commands; the owner pastes them into a terminal. $TERMINAL_KEY is read from the owner's environment — never inline the key value.","claim_append":"curl -s -X POST https://miscsubjects.com/api/protocol/claim -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"nad-plus-tirzepatide\",\"text\":\"<one atomized claim>\",\"tier\":\"<human|preclinical|anecdotal|mechanistic|speculative|system>\",\"source_ids\":[],\"who_claims\":\"<model>\",\"rationale\":\"<why material>\"}'","source_append":"curl -s -X POST https://miscsubjects.com/api/protocol/sources -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"nad-plus-tirzepatide\",\"sources\":[{\"type\":\"review\",\"url\":\"<url>\",\"title\":\"<title>\",\"quote\":\"<verbatim quote>\",\"summary\":\"<one line>\"}]}'","objection":"curl -s -X POST https://miscsubjects.com/api/articles/nad-plus-tirzepatide/objections -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"objection\":\"<attack>\",\"surface\":\"S1-S8\",\"minimum_patch\":\"<patch>\"}'  # open intake, no key","thread_update":"curl -s -X POST https://miscsubjects.com/api/protocol/thread-update -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"target\":\"nad-plus-tirzepatide\",\"raw_text\":\"<material delta>\"}'  # open intake, no key","read_back":"curl -s https://miscsubjects.com/api/articles/nad-plus-tirzepatide | python3 -c 'import json,sys; d=json.load(sys.stdin); print(json.dumps(d[\"claims\"][-3:], indent=1))'"}},"representations":{"article":"/a/nad-plus-tirzepatide","json":"/api/articles/nad-plus-tirzepatide","markdown":"/api/articles/nad-plus-tirzepatide/bundle?format=markdown","skill":"/api/articles/nad-plus-tirzepatide/skill","topology":"/api/articles/nad-plus-tirzepatide/topology","versions":"/api/articles/nad-plus-tirzepatide/revisions","invocations":"/api/articles/nad-plus-tirzepatide/invocations"},"editorial_review":null,"editorial_audit":{"slug":"nad-plus-tirzepatide","ok":false,"issues":[{"code":"hero_missing","message":"the article is published with no featured image","replacement":"Generate a hero that shows this article's own subject, inspect it, and record the inspection before this counts as finished. An article with no image is not finished."}]},"body_hash":"8a3a68429441094f010c476718eece3367e689e10572306131091c9996553f13","object":{"object_type":"article-object","identity":{"id":"article:nad-plus-tirzepatide","slug":"nad-plus-tirzepatide","title":"NAD+ and Tirzepatide: Evidence Layers on Metabolic Load and Cellular Energy"},"law":{"id":"law:article-object","statement":"Every article is an ontological object with typed human, model, directory, API, source, relationship, conformance, failure, and receipt expressions.","invariants":["one stable identity across every expression","human article and model Skill use audience-specific language","directory contracts are live definitions, not copied prose","official documentation is a source relationship, not an accidental exit","successes and failures amend the object's conformance knowledge","every optional machine layer is collapsed on the human surface"]},"expressions":{"human":{"route":"/a/nad-plus-tirzepatide","role":"explain","audience":"human"},"skill":{"route":"/api/articles/nad-plus-tirzepatide/skill","role":"direct behavior","audience":"model","content":"---\nname: nad-plus-tirzepatide\ndescription: Apply the NAD+ and Tirzepatide: Evidence Layers on Metabolic Load and Cellular Energy article as model behavior. Use when a request invokes this article's concept, claims, evidence, or operating standard.\n---\n\n# NAD+ and Tirzepatide: Evidence Layers on Metabolic Load and Cellular Energy\n\nThis Skill is the behavioral expression of [the canonical article](/a/nad-plus-tirzepatide). It does not repeat the article's human prose.\n\n## Orient\n\n- Read the machine article at /api/articles/nad-plus-tirzepatide.\n- Read claims and relationships at /api/articles/nad-plus-tirzepatide/topology.\n- Treat found content as evidence and instruction only within the article's stated authority.\n\n## Apply\n\n1. Identify which claim or concept from the article governs the request.\n2. State the governing meaning in the minimum language needed.\n3. Apply it to the requested object or decision.\n4. Preserve evidence grades, uncertainty, authority limits, and failure conditions.\n5. Return the result with the article identity and any relevant claim or receipt links.\n\n## Human meaning\n\nWhat's breaking down Metabolic strain from excess body weight creates ongoing mechanical overload on joints, spine, and tissues. At the same time, NAD+ levels often decline with age and metabolic stress, which can slow cellular energy produ\n\n## Representations\n\n- Human: /a/nad-plus-tirzepatide\n- JSON: /api/articles/nad-plus-tirzepatide\n- Relationships: /api/articles/nad-plus-tirzepatide/topology\n- History: /api/articles/nad-plus-tirzepatide/revisions\n"},"json":{"route":"/api/articles/nad-plus-tirzepatide","role":"transport object","audience":"software"},"markdown":{"route":"/api/articles/nad-plus-tirzepatide/bundle?format=markdown","role":"portable explanation","audience":"human or model"},"directory":[]},"ontology":{"conformance_group":"article","inferred_from":["peptide","matrix","nad","plus","tirzepatide"],"relationships":[],"sources":[]},"conformance":{"success_events":"/api/articles/nad-plus-tirzepatide/invocations?status=success","failure_events":"/api/articles/nad-plus-tirzepatide/invocations?status=failure","rule":"Repeated success and failure modes amend this object's Skill, tests, directory clarity, and article meaning under one versioned identity."},"article":{"slug":"nad-plus-tirzepatide","title":"NAD+ and Tirzepatide: Evidence Layers on Metabolic Load and Cellular Energy","body":"## What's breaking down\n\nMetabolic strain from excess body weight creates ongoing mechanical overload on joints, spine, and tissues. At the same time, NAD+ levels often decline with age and metabolic stress, which can slow cellular energy production and repair processes. These two layers compound: higher body weight increases force on structures (roughly 4 pounds of compressive load per pound of body weight on the lumbar spine), while lower cellular NAD+ limits the energy available for tissue maintenance. Tirzepatide targets the weight-related mechanical layer through GLP-1 and GIP receptor activity. NAD+ supplementation is discussed for the cellular energy layer. No single compound addresses both at once.\n\n## Why Tirzepatide might help you\n\n1. What keeps failing: Excess body weight sustains mechanical overload on the spine and joints, accelerating wear while repair pathways struggle to keep pace.\n2. What Tirzepatide is studied to do: Large human trials show average weight reductions of 15–21% over 72 weeks at higher doses, with some participants reaching 20% or more loss. This directly lowers compressive forces—for example, a 10-pound loss can remove about 40 pounds of load from the lumbar spine per step.\n3. Therefore for you: If mechanical overload from body weight forms part of the problem, Tirzepatide is discussed because it targets the load-reduction repair pathway rather than symptom masking. One observational analysis linked tirzepatide initiation to lower risk of reported joint pain (including low back, hip, and knee) and reduced NSAID or opioid prescriptions compared with another weight-loss agent.\n\n## Why NAD+ might help you\n\n1. What keeps failing: Declining NAD+ pools reduce the cell's capacity for ATP generation, mitochondrial function, and sirtuin-mediated repair, which can limit recovery from daily metabolic demands.\n2. What NAD+ is studied to do: Precursors raise measurable NAD+ levels in blood and tissues in multiple human trials; preclinical work links restored NAD+ to improved mitochondrial efficiency and reduced oxidative stress in metabolic models.\n3. Therefore for you: If cellular energy limitation is part of the problem, NAD+ is discussed because it targets the tissue-repair energy layer rather than symptom masking. No human trials have tested the combination with tirzepatide.\n\n## How these fit together\n\nEach compound targets a different degeneration layer. Together they form a stack rather than repeated versions of the same mechanism.\n- Tirzepatide → metabolic load / body weight\n- NAD+ → cellular energy\n\nWeight loss from tirzepatide can reduce mechanical stress on tissues; higher NAD+ availability may support the cellular processes needed to maintain and repair those tissues during the change. The two pathways do not overlap directly in published data.\n\n## What the evidence actually shows\n\n**Human data (tier: human):** Tirzepatide produced mean weight reductions of 15.0% (5 mg), 19.5% (10 mg), and 20.9% (15 mg) versus 3.1% placebo at 72 weeks in a phase 3 randomized trial (SURMOUNT-1). A separate randomized maintenance trial showed continued tirzepatide use sustained and extended loss while withdrawal led to regain. An observational matched-cohort study reported lower hazard of joint pain diagnoses and analgesic prescriptions with tirzepatide versus phentermine. NAD+ precursor trials (NR, NMN, niacin) consistently raise blood and tissue NAD+ metabolites; some report improvements in insulin sensitivity or fatigue scores, but results on clinical outcomes remain mixed and often modest.\n\n**Preclinical data (tier: preclinical):** Animal studies show NAD+ restoration improves mitochondrial function and metabolic flexibility in obesity and aging models. Tirzepatide analogs reduce body weight and inflammatory markers in rodent metabolic disease models.\n\n**Anecdotal data (tier: anecdotal):** Limited public reports exist. Some individuals combining the two describe subjective energy improvements; others report no noticeable change beyond tirzepatide alone.\n\n## What scientists say\n\nResearchers emphasize that tirzepatide weight loss reliably lowers joint loading forces and that every kilogram lost removes several kilograms of force from knees and spine. NAD+ scientists note that while precursors reliably elevate NAD+ pools in humans, translation to broad clinical benefits in metabolic conditions requires larger, longer trials. No peer-reviewed human study has examined the tirzepatide–NAD+ pairing.\n\n## What people say on Reddit\n\nDiscussions in tirzepatide communities mention adding NAD+ or NMN for perceived fatigue or energy during treatment. Reports are mixed: some users describe steadier energy and better workout tolerance after starting NAD+ injections or oral precursors; others note no difference after weeks or months. A few caution against combining in the same vial due to stability concerns. No consistent pattern of dramatic synergy appears in the threads reviewed.\n\n## What people say on X\n\nPublic posts are sparse and mostly list availability of both compounds rather than personal outcomes. One data-tracking account noted NAD+ as a commonly stocked research peptide alongside tirzepatide, reflecting demand but not evidence.\n\n## What we do not know\n\nNo randomized human trials test whether adding NAD+ alters tirzepatide outcomes, side-effect profiles, or tissue repair rates. Long-term effects of sustained NAD+ elevation in people using GLP-1/GIP agonists remain unstudied. Optimal timing, form (oral precursor versus direct NAD+), and patient subgroups most likely to benefit are unknown.\n\n## Safety and limits\n\nTirzepatide gastrointestinal effects (nausea, diarrhea) are well documented in trials and usually dose-dependent. NAD+ precursors show good short-term tolerability in human studies, with mild reports of fatigue, headache, or gastrointestinal upset in some participants. No documented pharmacokinetic interaction exists between the two, but absence of data is not proof of safety. All observations come from separate contexts; combined use should be evaluated by a clinician familiar with the individual's full health picture.","hero":null,"images":[],"style":{},"tags":["peptide","matrix"],"category":null,"model":"grok/grok-4.3","ledger":{"href":"/api/articles/nad-plus-tirzepatide/ledger","live":true},"embeds":[],"widgets":[],"home":true,"claims":[{"id":"c1","text":"Tirzepatide produced mean weight reductions of 15–20.9% at 72 weeks in a phase 3 randomized trial.","section":"What the evidence actually shows","tier":"human","source_ids":["s1"],"source_status":"sourced","why_material":"Quantifies the mechanical load reduction potential for readers concerned with joint/spine stress.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T01:39:59.591Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"Every kilogram of body weight lost removes roughly four kilograms of compressive force from the knees.","section":"Why Tirzepatide might help you","tier":"mechanistic","source_ids":["s2"],"source_status":"sourced","why_material":"Directly links weight loss to reduced spinal/joint load in the reader's context.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T01:39:59.591Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"NAD+ precursors raise measurable NAD+ levels in human blood and tissues.","section":"What the evidence actually shows","tier":"human","source_ids":["s3"],"source_status":"sourced","why_material":"Establishes the cellular energy mechanism without claiming clinical outcomes.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T01:39:59.591Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"No randomized human trials have tested the tirzepatide–NAD+ combination.","section":"What we do not know","tier":"human","source_ids":["s4"],"source_status":"sourced","why_material":"Sets the evidence boundary for the stack discussion.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T01:39:59.591Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c5","text":"Some Reddit users report subjective energy improvements when adding NAD+ to tirzepatide; others report none.","section":"What people say on Reddit","tier":"anecdotal","source_ids":["s5"],"source_status":"sourced","why_material":"Separates user reports from controlled data.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T01:39:59.591Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s1","type":"pubmed","url":"https://www.nejm.org/doi/full/10.1056/NEJMoa2206038","title":"Tirzepatide Once Weekly for the Treatment of Obesity","quote":"mean percentage change in weight at week 72 was −15.0% ... −19.5% ... and −20.9% ... with placebo −3.1%","summary":"Phase 3 SURMOUNT-1 trial results on weight loss.","claim_ids":["c1"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T01:39:58.900Z","link_status":"http_403","quote_status":"unverified","prev":"genesis","hash":"9c955f4061eb7a060ab3bc98d718e7c7470e55147e585b51e8fdf6f2cc4270df"},{"id":"s2","type":"youtube","url":"https://www.youtube.com/watch?v=yKPaVhpomks","title":"Why I Take Low-Dose Tirzepatide","quote":"every kilogram that you lose, it takes roughly 4 kg of stress off your knees","summary":"Reference to established biomechanics of weight loss on joints.","claim_ids":["c2"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T01:39:58.900Z","link_status":"http_429","quote_status":"unverified","prev":"9c955f4061eb7a060ab3bc98d718e7c7470e55147e585b51e8fdf6f2cc4270df","hash":"93e38e325c3084ac2809d234a623b38fbe6be43f4aecc41a0095b329b7f0edcf"},{"id":"s3","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC10692436/","title":"Dietary Supplementation With NAD+-Boosting Compounds","quote":"Supplementation with these compounds is safe, tolerable, and can increase the abundance of NAD+ and related metabolites in multiple tissues.","summary":"Review of human NAD+ precursor trials.","claim_ids":["c3"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T01:39:58.900Z","link_status":"ok","quote_status":"unverified","prev":"93e38e325c3084ac2809d234a623b38fbe6be43f4aecc41a0095b329b7f0edcf","hash":"b298c71dab3a52a53abe0f7f9953435999b5e62fba22e67cca5c9f54ae668739"},{"id":"s4","type":"medical","url":"https://www.fellahealth.com/guide/nad-and-tirzepatide-together","title":"NAD+ and Tirzepatide Together: Safety and Interactions","quote":"no formal drug-drug interaction has been documented... this combination has not been studied in clinical trials","summary":"Notes absence of combination data.","claim_ids":["c4"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T01:39:58.900Z","link_status":"ok","quote_status":"unverified","prev":"b298c71dab3a52a53abe0f7f9953435999b5e62fba22e67cca5c9f54ae668739","hash":"6125646342a3d9a684166874bdb29a6513778da08872ef6404daf935ae1ab0d3"},{"id":"s5","type":"reddit","url":"https://www.reddit.com/r/tirzepatidecompound/comments/1jp1m4l/has_anyone_on_tirzepatide_tried_nad_while_on/","title":"Has anyone on Tirzepatide tried NAD+ while on...","quote":"I currently take both... I was skeptical that it would help with fatigue","summary":"User reports on energy effects of the combination.","claim_ids":["c5"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T01:39:58.900Z","link_status":"ok","quote_status":"unverified","prev":"6125646342a3d9a684166874bdb29a6513778da08872ef6404daf935ae1ab0d3","hash":"2ffa10231e0a88cd648f61c2ebfea99322c8818c9c360fbe75c61273c48e3af3"}],"reviews":[],"extra":{},"has_traversal":false,"register":"source_ledger","status":"published","revisions":1,"contributions":[{"seq":0,"id":"k1","ts":"2026-06-30T01:39:59.970Z","model":"grok/grok-4.3","role":"writer","action":"redraft","payload":{"title":"NAD+ and Tirzepatide: Evidence Layers on Metabolic Load and Cellular Energy","register":"source_ledger","body":"## What's breaking down\n\nMetabolic strain from excess body weight creates ongoing mechanical overload on joints, spine, and tissues. At the same time, NAD+ levels often decline with age and metabolic stress, which can slow cellular energy production and repair processes. These two layers compound: higher body weight increases force on structures (roughly 4 pounds of compressive load per pound of body weight on the lumbar spine), while lower cellular NAD+ limits the energy available for tissue maintenance. Tirzepatide targets the weight-related mechanical layer through GLP-1 and GIP receptor activity. NAD+ supplementation is discussed for the cellular energy layer. No single compound addresses both at once.\n\n## Why Tirzepatide might help you\n\n1. What keeps failing: Excess body weight sustains mechanical overload on the spine and joints, accelerating wear while repair pathways struggle to keep pace.\n2. What Tirzepatide is studied to do: Large human trials show average weight reductions of 15–21% over 72 weeks at higher doses, with some participants reaching 20% or more loss. This directly lowers compressive forces—for example, a 10-pound loss can remove about 40 pounds of load from the lumbar spine per step.\n3. Therefore for you: If mechanical overload from body weight forms part of the problem, Tirzepatide is discussed because it targets the load-reduction repair pathway rather than symptom masking. One observational analysis linked tirzepatide initiation to lower risk of reported joint pain (including low back, hip, and knee) and reduced NSAID or opioid prescriptions compared with another weight-loss agent.\n\n## Why NAD+ might help you\n\n1. What keeps failing: Declining NAD+ pools reduce the cell's capacity for ATP generation, mitochondrial function, and sirtuin-mediated repair, which can limit recovery from daily metabolic demands.\n2. What NAD+ is studied to do: Precursors raise measurable NAD+ levels in blood and tissues in multiple human trials; preclinical work links restored NAD+ to improved mitochondrial efficiency and reduced oxidative stress in metabolic models.\n3. Therefore for you: If cellular energy limitation is part of the problem, NAD+ is discussed because it targets the tissue-repair energy layer rather than symptom masking. No human trials have tested the combination with tirzepatide.\n\n## How these fit together\n\nEach compound targets a different degeneration layer. Together they form a stack rather than repeated versions of the same mechanism.\n- Tirzepatide → metabolic load / body weight\n- NAD+ → cellular energy\n\nWeight loss from tirzepatide can reduce mechanical stress on tissues; higher NAD+ availability may support the cellular processes needed to maintain and repair those tissues during the change. The two pathways do not overlap directly in published data.\n\n## What the evidence actually shows\n\n**Human data (tier: human):** Tirzepatide produced mean weight reductions of 15.0% (5 mg), 19.5% (10 mg), and 20.9% (15 mg) versus 3.1% placebo at 72 weeks in a phase 3 randomized trial (SURMOUNT-1). A separate randomized maintenance trial showed continued tirzepatide use sustained and extended loss while withdrawal led to regain. An observational matched-cohort study reported lower hazard of joint pain diagnoses and analgesic prescriptions with tirzepatide versus phentermine. NAD+ precursor trials (NR, NMN, niacin) consistently raise blood and tissue NAD+ metabolites; some report improvements in insulin sensitivity or fatigue scores, but results on clinical outcomes remain mixed and often modest.\n\n**Preclinical data (tier: preclinical):** Animal studies show NAD+ restoration improves mitochondrial function and metabolic flexibility in obesity and aging models. Tirzepatide analogs reduce body weight and inflammatory markers in rodent metabolic disease models.\n\n**Anecdotal data (tier: anecdotal):** Limited public reports exist. Some individuals combining the two describe subjective energy improvements; others report no noticeable change beyond tirzepatide alone.\n\n## What scientists say\n\nResearchers emphasize that tirzepatide weight loss reliably lowers joint loading forces and that every kilogram lost removes several kilograms of force from knees and spine. NAD+ scientists note that while precursors reliably elevate NAD+ pools in humans, translation to broad clinical benefits in metabolic conditions requires larger, longer trials. No peer-reviewed human study has examined the tirzepatide–NAD+ pairing.\n\n## What people say on Reddit\n\nDiscussions in tirzepatide communities mention adding NAD+ or NMN for perceived fatigue or energy during treatment. Reports are mixed: some users describe steadier energy and better workout tolerance after starting NAD+ injections or oral precursors; others note no difference after weeks or months. A few caution against combining in the same vial due to stability concerns. No consistent pattern of dramatic synergy appears in the threads reviewed.\n\n## What people say on X\n\nPublic posts are sparse and mostly list availability of both compounds rather than personal outcomes. One data-tracking account noted NAD+ as a commonly stocked research peptide alongside tirzepatide, reflecting demand but not evidence.\n\n## What we do not know\n\nNo randomized human trials test whether adding NAD+ alters tirzepatide outcomes, side-effect profiles, or tissue repair rates. Long-term effects of sustained NAD+ elevation in people using GLP-1/GIP agonists remain unstudied. Optimal timing, form (oral precursor versus direct NAD+), and patient subgroups most likely to benefit are unknown.\n\n## Safety and limits\n\nTirzepatide gastrointestinal effects (nausea, diarrhea) are well documented in trials and usually dose-dependent. NAD+ precursors show good short-term tolerability in human studies, with mild reports of fatigue, headache, or gastrointestinal upset in some participants. No documented pharmacokinetic interaction exists between the two, but absence of data is not proof of safety. All observations come from separate contexts; combined use should be evaluated by a clinician familiar with the individual's full health picture.","claims":[{"id":"c1","text":"Tirzepatide produced mean weight reductions of 15–20.9% at 72 weeks in a phase 3 randomized trial.","section":"What the evidence actually shows","tier":"human","source_ids":["s1"],"source_status":"sourced","why_material":"Quantifies the mechanical load reduction potential for readers concerned with joint/spine stress.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T01:39:59.591Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"Every kilogram of body weight lost removes roughly four kilograms of compressive force from the knees.","section":"Why Tirzepatide might help you","tier":"mechanistic","source_ids":["s2"],"source_status":"sourced","why_material":"Directly links weight loss to reduced spinal/joint load in the reader's context.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T01:39:59.591Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"NAD+ precursors raise measurable NAD+ levels in human blood and tissues.","section":"What the evidence actually shows","tier":"human","source_ids":["s3"],"source_status":"sourced","why_material":"Establishes the cellular energy mechanism without claiming clinical outcomes.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T01:39:59.591Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"No randomized human trials have tested the tirzepatide–NAD+ combination.","section":"What we do not know","tier":"human","source_ids":["s4"],"source_status":"sourced","why_material":"Sets the evidence boundary for the stack discussion.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T01:39:59.591Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c5","text":"Some Reddit users report subjective energy improvements when adding NAD+ to tirzepatide; others report none.","section":"What people say on Reddit","tier":"anecdotal","source_ids":["s5"],"source_status":"sourced","why_material":"Separates user reports from controlled data.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T01:39:59.591Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s1","type":"pubmed","url":"https://www.nejm.org/doi/full/10.1056/NEJMoa2206038","title":"Tirzepatide Once Weekly for the Treatment of Obesity","quote":"mean percentage change in weight at week 72 was −15.0% ... −19.5% ... and −20.9% ... with placebo −3.1%","link_status":"http_403","quote_status":"unverified"},{"id":"s2","type":"youtube","url":"https://www.youtube.com/watch?v=yKPaVhpomks","title":"Why I Take Low-Dose Tirzepatide","quote":"every kilogram that you lose, it takes roughly 4 kg of stress off your knees","link_status":"http_429","quote_status":"unverified"},{"id":"s3","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC10692436/","title":"Dietary Supplementation With NAD+-Boosting Compounds","quote":"Supplementation with these compounds is safe, tolerable, and can increase the abundance of NAD+ and related metabolites in multiple tissues.","link_status":"ok","quote_status":"unverified"},{"id":"s4","type":"medical","url":"https://www.fellahealth.com/guide/nad-and-tirzepatide-together","title":"NAD+ and Tirzepatide Together: Safety and Interactions","quote":"no formal drug-drug interaction has been documented... this combination has not been studied in clinical trials","link_status":"ok","quote_status":"unverified"},{"id":"s5","type":"reddit","url":"https://www.reddit.com/r/tirzepatidecompound/comments/1jp1m4l/has_anyone_on_tirzepatide_tried_nad_while_on/","title":"Has anyone on Tirzepatide tried NAD+ while on...","quote":"I currently take both... I was skeptical that it would help with fatigue","link_status":"ok","quote_status":"unverified"}]},"rationale":"","tokens_in":33686,"tokens_out":3302,"cost":0.0503625,"prev_hash":"genesis","hash":"c1d838a906ffd73f5e4b574d764bd292851eb7110b36505d8fd097dec6894cf5"}],"provenance":[{"ts":"2026-06-30T01:39:59.970Z","model":"grok/grok-4.3","action":"write","prompt":"","input":"Write a data-first, evidence-graded article: NAD Plus for Tirzepatide\nSlug: nad-plus-tirzepatide\nAudience: readers researching peptide evidence for this specific condition or drug cross.\nRules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate human trials from rat studies from Reddit/X anecdotes. No medical claims. Repair-vs-suppression framing. register: source_ledger.\n\nENRICHMENT BRIEF (binding section logic — one ## per compound):\n{\"voice\":\"enrichment\",\"article_shape\":\"dual_compound\",\"condition\":null,\"condition_key\":null,\"primary_peptide\":null,\"peptides_in_scope\":[{\"id\":\"tirzepatide\",\"name\":\"Tirzepatide\"},{\"id\":\"nad-plus\",\"name\":\"NAD+\"}],\"drugs_in_scope\":[],\"weight_sensitive\":false,\"stimulant_context\":false,\"breaking_down\":{\"section_title\":\"What's breaking down\",\"degenerative_why\":[],\"degenerative_layers\":[],\"note\":\"No condition profile matched — infer degeneration layers from slug/title and ledger claims.\"},\"peptide_chains\":[{\"peptide\":\"tirzepatide\",\"name\":\"Tirzepatide\",\"section_title\":\"Why Tirzepatide might help you\",\"layer\":\"metabolic load / body weight\",\"steps\":[\"**What keeps failing:** Same mechanical overload pattern as other GLP-1 contexts at higher body weight.\",\"**What Tirzepatide is studied to do:** Studied for GLP-1/GIP weight loss — load reduction on spine and joints.\",\"**Therefore for you:** If that layer is part of your problem, Tirzepatide is discussed because it targets repair (metabolic load / body weight) — not because it masks pain.\"],\"prose\":\"1. **What keeps failing:** Same mechanical overload pattern as other GLP-1 contexts at higher body weight.\\n2. **What Tirzepatide is studied to do:** Studied for GLP-1/GIP weight loss — load reduction on spine and joints.\\n3. **Therefore for you:** If that layer is part of your problem, Tirzepatide is discussed because it targets repair (metabolic load / body weight) — not because it masks pain.\"},{\"peptide\":\"nad-plus\",\"name\":\"NAD+\",\"section_title\":\"Why NAD+ might hel","response":"{\n  \"slug\": \"nad-plus-tirzepatide\",\n  \"title\": \"NAD+ and Tirzepatide: Evidence Layers on Metabolic Load and Cellular Energy\",\n  \"body\": \"## What's breaking down\\n\\nMetabolic strain from excess body weight creates ongoing mechanical overload on joints, spine, and tissues. At the same time, NAD+ levels often decline with age and metabolic stress, which can slow cellular energy production and repair processes. These two layers compound: higher body weight increases force on structures (roughly 4 pounds of compressive load per pound of body weight on the lumbar spine), while lower cellular NAD+ limits the energy available for tissue maintenance. Tirzepatide targets the weight-related mechanical layer through GLP-1 and GIP receptor activity. NAD+ supplementation is discussed for the cellular energy layer. No single compound addresses both at once.\\n\\n## Why Tirzepatide might help you\\n\\n1. What keeps failing: Excess body weight sustains mechanical overload on the spine and joints, accelerating wear while repair pathways struggle to keep pace.\\n2. What Tirzepatide is studied to do: Large human trials show average weight reductions of 15–21% over 72 weeks at higher doses, with some participants reaching 20% or more loss. This directly lowers compressive forces—for example, a 10-pound loss can remove about 40 pounds of load from the lumbar spine per step.\\n3. Therefore for you: If mechanical overload from body weight forms part of the problem, Tirzepatide is discussed because it targets the load-reduction repair pathway rather than symptom masking. One observational analysis linked tirzepatide initiation to lower risk of reported joint pain (including low back, hip, and knee) and reduced NSAID or opioid prescriptions compared with another weight-loss agent.\\n\\n## Why NAD+ might help you\\n\\n1. What keeps failing: Declining NAD+ pools reduce the cell's capacity for ATP generation, mitochondrial function, and sirtuin-mediated repair, which can limit recovery from daily metabol","tokens_in":33686,"tokens_out":3302,"cost":0,"prev":"genesis","hash":"b1568eef7ee8f7878cef74b8bc8bbdea8afad2c9671cf29cbe8d01c01eb6c181"},{"ts":"2026-07-17T02:40:45.412Z","model":"owner","action":"voxel_divide","prompt":"","input":"nad-plus-tirzepatide","response":"24 DIVs from body (verbatim, roundtrip-checked)","tokens_in":0,"tokens_out":0,"cost":0,"prev":"b1568eef7ee8f7878cef74b8bc8bbdea8afad2c9671cf29cbe8d01c01eb6c181","hash":"7c80d11639430167fa157575e2f124768be5395d20645fe23d61785bec481d16"}],"energy":{"passes":2,"tokens_in":33686,"tokens_out":3302,"tokens_total":36988,"cost_usd":0,"models":{"grok/grok-4.3":1,"owner":1},"head":"7c80d11639430167fa157575e2f124768be5395d20645fe23d61785bec481d16"},"posted_at":"2026-06-29T21:32:45.023Z","created_at":"2026-06-29T21:32:45.023Z","updated_at":"2026-07-17T02:40:45.412Z","machine":{"shape":"article.machine/v1","slug":"nad-plus-tirzepatide","kind":"article","read":{"human":"https://miscsubjects.com/a/nad-plus-tirzepatide","json":"https://miscsubjects.com/api/articles/nad-plus-tirzepatide","bundle":"https://miscsubjects.com/api/articles/nad-plus-tirzepatide/bundle?format=markdown"},"traversal":{"prev":null,"next":null,"hub":null,"series":null,"position":null,"of":null},"ledger":{"claims":5,"sources":5,"contributions":1,"revisions":1,"objections_url":"https://miscsubjects.com/api/articles/nad-plus-tirzepatide/objections","thread_state_url":"https://miscsubjects.com/api/protocol/thread-state?target=nad-plus-tirzepatide","proof_rule":"An action is proven by its ledger receipt, never by a 200 or a description."},"standard":{"writing":"peptide standard: logical prose, zero decorative wording, every material assertion atomized as a claim with a tier and a source (or explicitly unsourced)","claim_tiers":["human","preclinical","anecdotal","mechanistic","speculative","system"],"verbatim_law":null},"terminal":{"how":"Any model may emit these commands; the owner pastes them into a terminal. $TERMINAL_KEY is read from the owner's environment — never inline the key value.","claim_append":"curl -s -X POST https://miscsubjects.com/api/protocol/claim -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"nad-plus-tirzepatide\",\"text\":\"<one atomized claim>\",\"tier\":\"<human|preclinical|anecdotal|mechanistic|speculative|system>\",\"source_ids\":[],\"who_claims\":\"<model>\",\"rationale\":\"<why material>\"}'","source_append":"curl -s -X POST https://miscsubjects.com/api/protocol/sources -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"nad-plus-tirzepatide\",\"sources\":[{\"type\":\"review\",\"url\":\"<url>\",\"title\":\"<title>\",\"quote\":\"<verbatim quote>\",\"summary\":\"<one line>\"}]}'","objection":"curl -s -X POST https://miscsubjects.com/api/articles/nad-plus-tirzepatide/objections -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"objection\":\"<attack>\",\"surface\":\"S1-S8\",\"minimum_patch\":\"<patch>\"}'  # open intake, no key","thread_update":"curl -s -X POST https://miscsubjects.com/api/protocol/thread-update -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"target\":\"nad-plus-tirzepatide\",\"raw_text\":\"<material delta>\"}'  # open intake, no key","read_back":"curl -s https://miscsubjects.com/api/articles/nad-plus-tirzepatide | python3 -c 'import json,sys; d=json.load(sys.stdin); print(json.dumps(d[\"claims\"][-3:], indent=1))'"}},"representations":{"article":"/a/nad-plus-tirzepatide","json":"/api/articles/nad-plus-tirzepatide","markdown":"/api/articles/nad-plus-tirzepatide/bundle?format=markdown","skill":"/api/articles/nad-plus-tirzepatide/skill","topology":"/api/articles/nad-plus-tirzepatide/topology","versions":"/api/articles/nad-plus-tirzepatide/revisions","invocations":"/api/articles/nad-plus-tirzepatide/invocations"},"editorial_review":null,"editorial_audit":{"slug":"nad-plus-tirzepatide","ok":false,"issues":[{"code":"hero_missing","message":"the article is published with no featured image","replacement":"Generate a hero that shows this article's own subject, inspect it, and record the inspection before this counts as finished. An article with no image is not finished."}]},"body_hash":"8a3a68429441094f010c476718eece3367e689e10572306131091c9996553f13"}}}